136 related articles for article (PubMed ID: 31065112)
1. Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men.
Moustsen IR; Larsen SB; Duun-Henriksen AK; Tjønneland A; Kjær SK; Brasso K; Johansen C; Dalton SO
Br J Cancer; 2019 May; 120(11):1067-1074. PubMed ID: 31065112
[TBL] [Abstract][Full Text] [Related]
2. The association between education and risk of major cardiovascular events among prostate cancer patients: a study from the Diet, Cancer and Health study.
Moustsen IR; Friberg AS; Larsen SB; Duun-Henriksen AK; Tjønneland A; Kjaer SK; Brasso K; Johansen C; Dalton SO
Acta Oncol; 2019 May; 58(5):715-721. PubMed ID: 30757932
[No Abstract] [Full Text] [Related]
3. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study.
Matthes KL; Pestoni G; Korol D; Van Hemelrijck M; Rohrmann S
Urol Oncol; 2018 Jun; 36(6):309.e15-309.e23. PubMed ID: 29576269
[TBL] [Abstract][Full Text] [Related]
4. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
Jespersen CG; Nørgaard M; Borre M
Eur Urol; 2014 Apr; 65(4):704-9. PubMed ID: 23433805
[TBL] [Abstract][Full Text] [Related]
5. Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden.
Van Hemelrijck M; Garmo H; Holmberg L; Stattin P; Adolfsson J
Eur Urol; 2012 Apr; 61(4):690-700. PubMed ID: 21945719
[TBL] [Abstract][Full Text] [Related]
6. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.
Van Hemelrijck M; Garmo H; Lindhagen L; Bratt O; Stattin P; Adolfsson J
Eur Urol; 2017 Oct; 72(4):534-541. PubMed ID: 27816297
[TBL] [Abstract][Full Text] [Related]
7. Treatment with curative intent and survival in men with high-risk prostate cancer. A population-based study of 11 380 men with serum PSA level 20-100 ng/mL.
Ladjevardi S; Berglund A; Varenhorst E; Bratt O; Widmark A; Sandblom G
BJU Int; 2013 Mar; 111(3):381-8. PubMed ID: 22758210
[TBL] [Abstract][Full Text] [Related]
8. Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study.
Kariburyo F; Wang Y; Cheng IE; Wang L; Morgenstern D; Xie L; Meadows E; Danella J; Cher ML
BMC Urol; 2018 Jun; 18(1):55. PubMed ID: 29866100
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
[TBL] [Abstract][Full Text] [Related]
10. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden.
Van Hemelrijck M; Garmo H; Holmberg L; Ingelsson E; Bratt O; Bill-Axelson A; Lambe M; Stattin P; Adolfsson J
J Clin Oncol; 2010 Jul; 28(21):3448-56. PubMed ID: 20567006
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.
Banerji JS; Hurwitz LM; Cullen J; Wolff EM; Levie KE; Rosner IL; Brand TC; LʼEsperance JO; Sterbis JR; Porter CR
Urol Oncol; 2017 May; 35(5):234-242. PubMed ID: 28110975
[TBL] [Abstract][Full Text] [Related]
12. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center.
Thomsen FB; Mikkelsen MK; Hansen RB; Krug AH; Glenthøj A; Stattin P; Brasso K
Acta Oncol; 2016 Dec; 55(12):1456-1460. PubMed ID: 27333339
[TBL] [Abstract][Full Text] [Related]
15. Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer.
Crawley D; Garmo H; Rudman S; Stattin P; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
BJU Int; 2018 Feb; 121(2):209-216. PubMed ID: 28418195
[TBL] [Abstract][Full Text] [Related]
16. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
17. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
[TBL] [Abstract][Full Text] [Related]
18. Active surveillance for localized prostate cancer: update of a prospective single-center cohort.
Thostrup M; Thomsen FB; Iversen P; Brasso K
Scand J Urol; 2018 Feb; 52(1):14-19. PubMed ID: 28958194
[TBL] [Abstract][Full Text] [Related]
19. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke.
Hayes JH; Chen MH; Moran BJ; Braccioforte MH; Dosoretz DE; Salenius S; Katin MJ; Ross R; Choueiri TK; D'Amico AV
BJU Int; 2010 Oct; 106(7):979-85. PubMed ID: 20230380
[TBL] [Abstract][Full Text] [Related]
20. Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden.
Nugin H; Folkvaljon Y; Damber JE; Adolfsson J; Robinson D; Stattin P
Scand J Urol; 2018 Aug; 52(4):277-284. PubMed ID: 30362868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]